Breast Cancer

Rebecca Shatsky, MD, University of California, San Diego

Videos

Datopotamab Deruxtecan Plus Durvalumab for Certain Patients With Advanced Breast Cancer

06/07/2024

Rebecca Shatsky, MD

Rebecca Shatsky, MD, shares results on datopotamab deruxtecan plus durvalumab for certain patients with advanced breast cancer from the I-SPY2.2 trial.

Rebecca Shatsky, MD, shares...

06/07/2024

Oncology

VIDEOS

Lasofoxifene vs Fulvestrant for ESR1-Mutated Metastatic Breast Cancer With Progression on CDK4/6 Inhibitors

09/15/2022

Matthew Goetz, MD, highlights findings from the ELAINE 1 trial exploring lasofoxifene vs fulvestrant for patients with ESR1-mutated locally advanced or metastatic breast cancer who progressed on aromatase and CDK4/6 inhibitors.

Matthew Goetz, MD, highlights...

09/15/2022

Oncology

VIDEOS

Abemaciclib Added to a Nonsteroidal Aromatase Inhibitor Improves OS in HR-Positive, HER2-Negative Breast Cancer

09/14/2022

Matthew Goetz, MD, discusses a second interim analysis on OS results for the MONARCH 3 trial, demonstrating prolonged OS with the addition of abemaciclib to a nonsteroidal aromatase inhibitor in patients with HR-positive, HER2-negative...

Matthew Goetz, MD, discusses a...

09/14/2022

Oncology

Sara Tolaney, MD, Dana-Farber Cancer Institute

VIDEOS

Amcenestrant vs Physician’s Choice of Endocrine Therapy in ER-Positive, HER2-Negative Breast Cancer

09/13/2022

Sara Tolaney, MD, discusses results from AMEERA-3, an open-label randomized phase 2 trial that explored amcenestrant vs physician’s choice of endocrine therapy in patients with endocrine-resistant ER-positive, HER2-negative advanced breast...

Sara Tolaney, MD, discusses...

09/13/2022

Oncology

Podcasts

Dr Loprinzi Reviews Hot Flash Treatment Strategies in BC, Part II

03/15/2022

In part two of this interview, Charles Loprinzi, MD, Mayo Clinic, highlights some non-estrogenic approaches to hot flash management for patients with breast cancer, presented at the 39th Annual Miami Breast Cancer Conference.

In part two of this interview,...

03/15/2022

Oncology

Podcasts

Dr Loprinzi Reviews Hot Flash Treatment Strategies in BC, Part I

03/14/2022

In part one of this interview, Charles Loprinzi, MD, Mayo Clinic, highlights some non-estrogenic approaches to hot flash management for patients with breast cancer, presented at the 39th Annual Miami Breast Cancer Conference.

In part one of this interview,...

03/14/2022

Oncology

Videos

Tackling Technical Assessment Challenges in HER2-Low BC Space

02/28/2022

In part 4 of this series, Elisa Agostinetto, MD, Institut Jules Bordet, discusses the challenges of technical assessment in the HER2-low breast cancer treatment space.

In part 4 of this series, Elisa...

02/28/2022

Oncology

Videos

Future Developments in HER2-Low BC Featuring Dr Agostinetto

02/28/2022

In part three of this series, Dr Agostinetto, Institut Jules Bordet, highlights future trial developments in the HER2-low breast cancer space such as DESTINY-breast-04, DESTINY-breast-06, and DEBBRAH study.

In part three of this series, Dr...

02/28/2022

Oncology

Elisa Agostinetto, MD, Institut Jules Bordet

Videos

Promising New Therapies for HER2-Low Breast Cancer

02/28/2022

In part 2 of this series, Dr Agostinetto, Institut Jules Bordet, discusses several effective, promising agents in HER2-low breast cancer treatment.

In part 2 of this series, Dr...

02/28/2022

Oncology

Videos

Sara Hurvitz, MD, Discusses Trials on Tucatinib Therapy for HER2+ Metastatic Breast Cancer

11/28/2021

Dr Hurvitz discusses the HER2CLIMB and HER2CLIMB-02 trials examining tucatinib's activity and safety in patients with HER2-positive metastatic breast cancer.

Dr Hurvitz discusses the...

11/28/2021

Oncology